ImmunityBio
IBRX
60 hedge funds and large institutions have $57.4M invested in ImmunityBio in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.16% more ownership
Funds ownership: 19.55% → 19.72% (+0.16%)
12% less funds holding
Funds holding: 68 → 60 (-8)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
38% less capital invested
Capital invested by funds: $92.1M → $57.4M (-$34.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.2M |
| 2 |
Renaissance Technologies
New York
|
+$2.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$793K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$681K |
| 5 |
Barclays
London,
United Kingdom
|
+$411K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.07M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$631K |
| 3 |
Millennium Management
New York
|
-$525K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$209K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$186K |
IBRX Hedge Fund Activity: Q1 2017 in Review
60 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2017, worth a combined $57.4M — down 38% from $92.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IBRX and 6 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was Fidelity Investments, cutting an estimated $2.07M.
- 60 institutional investors held ImmunityBio (IBRX) as of Q1 2017, down from 68 in Q4 2016.
- Funds reported $57.4M of ImmunityBio stock for Q1 2017, down 38% quarter-over-quarter.
- 6 funds opened new ImmunityBio positions in Q1 2017 and 9 closed out, a net change of -3 holders.
- The largest ImmunityBio buyer in Q1 2017 was BlackRock, an estimated $10.2M added.
- The largest ImmunityBio seller in Q1 2017 was Fidelity Investments, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2017.